Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump

• Published in: mBio 2020-06, Vol.11 (3)
• Main Authors: Grimsey, Elizabeth M, Fais, Chiara, Marshall, Robert L, Ricci, Vito, Ciusa, Maria Laura, Stone, Jack W, Ivens, Alasdair, Malloci, Giuliano, Ruggerone, Paolo, Vargiu, Attilio V, Piddock, Laura J V
• Format: Article
• Language: English
• Subjects: AcrB; Amitriptyline - pharmacology; Anti-Bacterial Agents - pharmacology; antibiotic resistance; antipsychotic drugs; Bacterial Proteins - antagonists & inhibitors; Bacterial Proteins - genetics; Chlorpromazine - pharmacology; Drug Resistance, Multiple, Bacterial; efflux pump inhibitors; efflux pumps; Escherichia coli - drug effects; Escherichia coli - genetics; Escherichia coli Proteins - antagonists & inhibitors; Escherichia coli Proteins - genetics; Membrane Transport Proteins - genetics; Microbial Sensitivity Tests; Molecular Docking Simulation; Multidrug Resistance-Associated Proteins - antagonists & inhibitors; Multidrug Resistance-Associated Proteins - genetics; Mutation; Protein Binding; Salmonella enterica - drug effects; Salmonella enterica - genetics; Therapeutics and Prevention
• ISSN: 2161-2129; 2150-7511
• DOI: 10.1128/mBio.00465-20

Efflux is an important mechanism in Gram-negative bacteria conferring multidrug resistance. Inhibition of efflux is an encouraging strategy to restore the antibacterial activity of antibiotics. Chlorpromazine and amitriptyline have been shown to behave as efflux inhibitors. However, their mode of action is poorly understood. Exposure of serovar Typhimurium and to chlorpromazine selected for mutations within genes encoding RamR and MarR, regulators of the multidrug tripartite efflux pump AcrAB-TolC. Further experiments with Typhimurium containing AcrB D408A (a nonfunctional efflux pump) and chlorpromazine or amitriptyline resulted in the reversion of the mutant allele to the wild type. Together, this suggests these drugs are AcrB efflux substrates. Subsequent docking studies with AcrB from Typhimurium and , followed by molecular dynamics simulations and free energy calculations showed that chlorpromazine and amitriptyline bind at the hydrophobic trap, a preferred binding site for substrates and inhibitors within the distal binding pocket of AcrB. Based on these simulations, we suggest that chlorpromazine and amitriptyline inhibit AcrB-mediated efflux by interfering with substrate binding. Our findings provide evidence that these drugs are substrates and inhibitors of AcrB, yielding molecular details of their mechanism of action and informing drug discovery of new efflux inhibitors. Efflux pumps of the resistance nodulation-cell division (RND) superfamily are major contributors to multidrug resistance for most of the Gram-negative ESKAPE ( , , , , , and species) pathogens. The development of inhibitors of these pumps would be highly desirable; however, several issues have thus far hindered all efforts at designing new efflux inhibitory compounds devoid of adverse effects. An alternative route to design relies on the use of marketed drugs, for which side effects on human health have been already assessed. In this work, we provide experimental evidence that the antipsychotic drugs chlorpromazine and amitriptyline are inhibitors of the AcrB transporter, the engine of the major RND efflux pumps in and serovar Typhimurium. Furthermore, calculations have provided a molecular-level picture of the inhibition mechanism, allowing rationalization of experimental data and paving the way for similar studies with other classes of marketed compounds.